Healthcare

Veterinary Dermatology Drugs Market Size To Cross USD 20.95 Bn By 2030

The global veterinary dermatology drugs market size accounted for US$ 9.25  Bn in 2022 and is projected to reach around USD 20.95 Bn by 2030, growing at a CAGR of 10.76% from 2022 to 2030.

Veterinary Dermatology Drugs Market Size 2022 To 2030

Report Summary

The global veterinary dermatology drugs market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the veterinary dermatology drugs market across the globe.

A comprehensive estimate on the veterinary dermatology drugs market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of veterinary dermatology drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2418

Veterinary Dermatology Drugs Market  Report Scope 

Report CoverageDetails
Market Size in 2022USD 9.25 Billion
Market Size by 2030USD 20.95 Billion
Growth Rate from 2022 to 2030CAGR of 10.76%
Largest MarketNorth America
Fastest Growing MarketAsia Pacific
Base Year2021
Forecast Period2022 to 2030
Segments Covered
  • By Animal Type
  • By Route of Administration
  • By Indication
  • By Distribution Channel

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized veterinary dermatology drugs market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: US Virtual Care Market Size To Cross USD 51.2 Bn By 2030

Veterinary Dermatology Drugs Market  Players

The report includes the profiles of key veterinary dermatology drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Merial, Zoetis, Inc.
  • Ceva Sante Animale
  • Vetmedica
  • IDEXX Laboratories
  • Vetoquinol S.A.
  • Virbac S.A.
  • Bayer Animal Health
  • Boehringer Ingelheim
  • Elanco
  • Novartis Animal Health
  • SAVAVET
  • Toray Industries
  • AB Science

Market Segmentation

By Animal Type

  • Companion Animal
  • Livestock Animal

By Route of Administration

  • Oral
  • Topical
  • Injectable

By Indication

  • Parasitic Infections
  • Allergic Infections
  • Others

By Distribution Channel

  • Retail
  • E-Commerce
  • Hospital Pharmacies

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Veterinary Dermatology Drugs Market 

5.1. COVID-19 Landscape: Veterinary Dermatology Drugs Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Veterinary Dermatology Drugs Market, By Animal Type

8.1. Veterinary Dermatology Drugs Market, by Animal Type, 2022-2030

8.1.1. Companion Animal

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Livestock Animal

Chapter 9. Global Veterinary Dermatology Drugs Market, By Route of Administration

9.1. Veterinary Dermatology Drugs Market, by Route of Administration, 2022-2030

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Topical

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Injectable

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Veterinary Dermatology Drugs Market, By Indication 

10.1. Veterinary Dermatology Drugs Market, by Indication, 2022-2030

10.1.1. Parasitic Infections

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Allergic Infections

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Veterinary Dermatology Drugs Market, By Distribution Channel 

11.1. Veterinary Dermatology Drugs Market, by Distribution Channel, 2022-2030

11.1.1. Retail

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. E-Commerce

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Hospital Pharmacies

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Veterinary Dermatology Drugs Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.1.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.3. Market Revenue and Forecast, by Indication (2017-2030)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Indication (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Indication (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.2.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.3. Market Revenue and Forecast, by Indication (2017-2030)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Indication (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Indication (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Indication (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Indication (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.3.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.3. Market Revenue and Forecast, by Indication (2017-2030)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Indication (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Indication (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Indication (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Indication (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.3. Market Revenue and Forecast, by Indication (2017-2030)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Indication (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Indication (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Indication (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Indication (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.3. Market Revenue and Forecast, by Indication (2017-2030)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Indication (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Indication (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13. Company Profiles

13.1. Merial, Zoetis, Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Ceva Sante Animale

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Vetmedica

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. IDEXX Laboratories

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Vetoquinol S.A.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Virbac S.A.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Bayer Animal Health

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Boehringer Ingelheim

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Elanco

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Novartis Animal Health

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

Show More

Related Articles

Back to top button